Sarepta Therapeutics Inc (SRPT): Rasio utang marang kapitalisasi buku

Lambang korporat lan logo Sarepta Therapeutics, Inc. (SRPT)

The confirmed price history on the Sarepta Therapeutics, Inc. (SRPT) chart demonstrates growth amounting to 0.68. The business is currently aggressively expanding the global market presence of its gene therapies following new regulatory approvals. The operating model relies on external contractors for drug manufacturing while maintaining strict patent control. A monopoly position in the treatment of orphan diseases allows Sarepta Therapeutics, Inc. (SRPT) to exercise independent pricing power over its therapies.

Sarepta Therapeutics, Inc. - Utang-utang marang kapitalisasi buku SRPT (periode 04.07.2022 - 30.10.2026)
Sampel barang Sarepta Therapeutics Inc

For Sarepta Therapeutics, Inc. (SRPT), its patent monopoly in gene therapy combined with low debt levels confirms financial autonomy and the ability to maintain high margins without pressure from creditors. By analyzing the ratio of total liabilities to book capitalization, an investor assesses the proportion of borrowed funds within the equity structure, which helps determine the business's resilience to currency fluctuations and the risk of cash flow gaps during acquisitions.

Perusahaan pesaing

Utang-utang marang kapitalisasi buku TEM (Tempus AI Inc)|Utang-utang marang kapitalisasi buku qiagen.com QGEN|IONS - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Repligen Corp RGEN|RNA: Utang-utang marang kapitalisasi buku|CRISPR (CRSP) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku GeneDx Holdings Corp.|RARE: Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku BEAM|TWST - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku 10x Genomics Corp TXG|NTLA (Intellia Corp) - Rasio utang-utang marang kapitalisasi buku|STOK: Utang marang nilai buku|biolifesolutions.com - Utang marang modal buku|WVE: Utang-utang marang kapitalisasi buku|Maze Therapeutics, Inc. (MAZE) - Utang-utang marang kapitalisasi buku|Utang marang nilai buku SION|PRME: Rasio utang marang aset resik|Utang marang nilai buku TSHA (Taysha Gene Therapies)|Utang marang modal buku QURE|Utang-utang marang kapitalisasi buku MGTX (MeiraGTx)|Rasio utang marang aset resik RGNX|Solid Bio - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Ocugen Pharma|Pacific Biosciences (PACB) - Rasio utang marang kapitalisasi buku|benitec.com - Rasio utang marang aset resik|DSGN (Design Therapeutics, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Rocket Pharma|Rasio utang marang kapitalisasi buku 4D Molecular Therapeutics Inc (FDMT)|LXEO: Rasio utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku KRRO (Korro Bio)|editasmedicine.com (EDIT) - Utang-utang marang nilai buku|SLN: Utang marang nilai buku|PRQR - Utang-utang marang kapitalisasi buku|CDXS (codexis.com) - Utang marang nilai buku|SGMO: Utang marang modal buku|NAUT (Nautilus Biotechnology, Inc.) - Utang-utang marang kapitalisasi buku|metagenomi.co (MGX) - Utang-utang marang aset resik|Utang-utang marang kapitalisasi buku DTIL|Utang marang nilai buku generationbio.com GBIO|Rasio utang marang kapitalisasi buku Boundless Bio, Inc BOLD|Utang-utang marang aset resik Exicure Inc. (XCUR)|IMNN: Utang marang nilai buku|Rasio utang marang aset resik PHIO (Phio Pharmaceuticals)|MBIO: Utang-utang marang kapitalisasi buku|RNAZ - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Bionano Genomics Inc.|Rasio utang marang nilai buku APDN (Applied DNA Corp)|Utang-utang marang kapitalisasi buku BLUE|Utang marang nilai buku immunoprecise.com IPA|Omega Therapeutics, Inc. - Utang marang nilai buku|Utang-utang marang aset resik Singular Genomics Systems, Inc. (OMIC)|RGLS - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Syros Pharmaceuticals, Inc SYRS|Telesis Bio, Inc. (TBIO) - Rasio utang marang kapitalisasi buku|traconpharma.com - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku Unity Biotechnology, Inc.